Pathophysiology of Migraine.

Journal

Continuum (Minneapolis, Minn.)

ISSN: 1538-6899

Titre abrégé: Continuum (Minneap Minn)

Pays: United States

ID NLM: 9509333

Informations de publication

Date de publication:
01 Apr 2024

Historique:

medline: 3 4 2024

pubmed: 3 4 2024

entrez: 3 4 2024

Statut: ppublish

Résumé

This article provides an overview of the current understanding of migraine pathophysiology through insights gained from the extended symptom spectrum of migraine, neuroanatomy, migraine neurochemistry, and therapeutics. Recent advances in human migraine research, including human experimental migraine models and functional neuroimaging, have provided novel insights into migraine attack initiation, neurochemistry, neuroanatomy, and therapeutic substrates. It has become clear that migraine is a neural disorder, in which a wide range of brain areas and neurochemical systems are implicated, producing a heterogeneous clinical phenotype. Many of these neural pathways are monoaminergic and peptidergic, such as those involving calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide. We are currently witnessing an exciting era in which specific drugs targeting these pathways have shown promise in treating migraine, including some studies suggesting efficacy before headache has even started. Migraine is a brain disorder involving both headache and altered sensory, limbic, and homeostatic processing. A complex interplay between neurotransmitter systems, physiologic systems, and pain processing likely occurs. Targeting various therapeutic substrates within these networks provides an exciting avenue for future migraine therapeutics.

Identifiants

DOI: 10.1212/CON.0000000000001412 PMID: 38568486

pubmed: 38568486

doi: 10.1212/CON.0000000000001412

pii: 00132979-202404000-00005

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

325-343

Informations de copyright

Références

Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet Lond Engl 2015;386(9995):743–800. doi:10.1016/S0140-6736(15)60692-4

doi: 10.1016/S0140-6736(15)60692-4

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia Int J Headache 2018;38(1):1–211. doi:10.1177/0333102417738202

doi: 10.1177/0333102417738202

Karsan N, Goadsby PJ. Biological insights from the premonitory symptoms of migraine. Nat Rev Neurol 2018;14(12):699–710. doi:10.1038/s41582-018-0098-4

doi: 10.1038/s41582-018-0098-4

Schulte LH, Mehnert J, May A. Longitudinal neuroimaging over 30 days: temporal characteristics of migraine. Ann Neurol 2020;87(4):646–651. doi:10.1002/ana.25697

doi: 10.1002/ana.25697

Mehnert J, Fischer-Schulte L, May A. Aura phenomena do not initiate migraine attacks-Findings from neuroimaging. Headache 2023;63(8):1040–1044. doi:10.1111/head.14597

doi: 10.1111/head.14597

Karsan N, Goadsby PJ. Neuroimaging in the pre-ictal or premonitory phase of migraine: a narrative review. J Headache Pain 2023;24(1):106. doi:10.1186/s10194-023-01617-x

doi: 10.1186/s10194-023-01617-x

Karsan N, Nagaraj K, Goadsby PJ. Cranial autonomic symptoms: prevalence, phenotype and laterality in migraine and two potentially new symptoms. J Headache Pain 2022;23(1):18. doi:10.1186/s10194-022-01389-w

doi: 10.1186/s10194-022-01389-w

Karsan N, Peréz-Rodríguez A, Nagaraj K, Bose PR, Goadsby PJ. The migraine postdrome: spontaneous and triggered phenotypes. Cephalalgia Int J Headache 2021;41(6):721–730. doi:10.1177/0333102420975401

doi: 10.1177/0333102420975401

Russell MB, Rasmussen BK, Fenger K, Olesen J. Migraine without aura and migraine with aura are distinct clinical entities: a study of four hundred and eighty-four male and female migraineurs from the general population. Cephalalgia Int J Headache 1996;16(4):239–245. doi:10.1046/j.1468-2982.1996.1604239.x

doi: 10.1046/j.1468-2982.1996.1604239.x

Ahn AH. On the temporal relationship between throbbing migraine pain and arterial pulse. Headache 2010;50(9):1507–1510. doi:10.1111/j.1526-4610.2010.01765.x

doi: 10.1111/j.1526-4610.2010.01765.x

Amin FM, Asghar MS, Hougaard A, et al. Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study. Lancet Neurol 2013;12(5):454–461. doi:10.1016/S1474-4422(13)70067-X

doi: 10.1016/S1474-4422(13)70067-X

Schoonman GG, van der Grond J, Kortmann C, et al. Migraine headache is not associated with cerebral or meningeal vasodilatation–a 3 T magnetic resonance angiography study. Brain J Neurol 2008;131(Pt 8):2192–2200. doi:10.1093/brain/awn094

doi: 10.1093/brain/awn094

Ashina M, Reuter U, Smith T, et al. Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study. Cephalalgia Int J Headache 2021;41(3):294–304. doi:10.1177/0333102421989232

doi: 10.1177/0333102421989232

Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992;13(8):307–311. doi:10.1016/0165-6147(92)90097-p

doi: 10.1016/0165-6147(92)90097-p

Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J Neurosci 1987;7(12):4129–4136. doi:10.1523/JNEUROSCI.07-12-04129.1987

doi: 10.1523/JNEUROSCI.07-12-04129.1987

Peroutka SJ. Neurogenic inflammation and migraine: implications for the therapeutics. Mol Interv 2005;5(5):304–311. doi:10.1124/mi.5.5.10

doi: 10.1124/mi.5.5.10

Palm-Meinders IH, Koppen H, Terwindt GM, et al. Structural brain changes in migraine. JAMA 2012;308(18):1889–1897. doi:10.1001/jama.2012.14276

doi: 10.1001/jama.2012.14276

Schramm S, Börner C, Reichert M, et al. Functional magnetic resonance imaging in migraine: a systematic review. Cephalalgia Int J Headache 2023;43(2):3331024221128278. doi:10.1177/03331024221128278

doi: 10.1177/03331024221128278

Amin FM, Hougaard A, Cramer SP, et al. Intact blood-brain barrier during spontaneous attacks of migraine without aura: a 3 T DCE-MRI study. Eur J Neurol 2017;24(9):1116–1124. doi:10.1111/ene.13341

doi: 10.1111/ene.13341

Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci 2011;12(10):570–584. doi:10.1038/nrn3057

doi: 10.1038/nrn3057

Noseda R, Jakubowski M, Kainz V, Borsook D, Burstein R. Cortical projections of functionally identified thalamic trigeminovascular neurons: implications for migraine headache and its associated symptoms. J Neurosci Off J Soc Neurosci 2011;31(40):14204–14217. doi:10.1523/JNEUROSCI.3285-11.2011

doi: 10.1523/JNEUROSCI.3285-11.2011

Karsan N, Goadsby PJ. Migraine is more than just headache: is the link to chronic fatigue and mood disorders simply due to shared biological systems? Front Hum Neurosci 2021;15:646692. doi:10.3389/fnhum.2021.646692

doi: 10.3389/fnhum.2021.646692

Olesen J, Burstein R, Ashina M, Tfelt-Hansen P. Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol 2009;8(7):679–690. doi:10.1016/S1474-4422(09)70090-0

doi: 10.1016/S1474-4422(09)70090-0

Karsan N, Goadsby PJ. Imaging the premonitory phase of migraine. Front Neurol 2020;11:140. doi:10.3389/fneur.2020.00140

doi: 10.3389/fneur.2020.00140

Giffin NJ, Ruggiero L, Lipton RB, et al. Premonitory symptoms in migraine: an electronic diary study. Neurology 2003;60(6):935–940. doi:10.1212/01.wnl.0000052998.58526.a9

doi: 10.1212/01.wnl.0000052998.58526.a9

Quintela E, Castillo J, Muñoz P, Pascual J. Premonitory and resolution symptoms in migraine: a prospective study in 100 unselected patients. Cephalalgia Int J Headache 2006;26(9):1051–1060. doi:10.1111/j.1468-2982.2006.01157.x

doi: 10.1111/j.1468-2982.2006.01157.x

Dodick DW, Goadsby PJ, Schwedt TJ, et al. Ubrogepant for the acute treatment of migraine when administered during the prodrome: a phase 3, randomised, double-blind, placebo-controlled, crossover trial in the USA. Lancet 2023;402(10419):2307–2316. doi:10.1016/S0140-6736(23)01683-5

doi: 10.1016/S0140-6736(23)01683-5

Ashina S, Melo-Carrillo A, Toluwanimi A, et al. Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-responders. J Headache Pain 2023;24(1):26. doi:10.1186/s10194-023-01560-x

doi: 10.1186/s10194-023-01560-x

Waelkens J. Dopamine blockade with domperidone: bridge between prophylactic and abortive treatment of migraine? A dose-finding study. Cephalalgia Int J Headache 1984;4(2):85–90. doi:10.1046/j.1468-2982.1984.0402085.x

doi: 10.1046/j.1468-2982.1984.0402085.x

Waelkens J. Domperidone in the prevention of complete classical migraine. Br Med J Clin Res Ed 1982;284(6320):944. doi:10.1136/bmj.284.6320.944

doi: 10.1136/bmj.284.6320.944

Massiou H. Dihydroergotamine nasal spray in prevention and treatment of migraine attacks: two controlled trials versus placebo. Cephalalgia 1987;7(6 Suppl):440–441. doi:10.1177/03331024870070S6195

doi: 10.1177/03331024870070S6195

Jenzer G, Bremgartner MF. Dihydroergotamin als Nasalspray in der Therapie des Migräneanfalls. Wirksamkeit und Verträglichkeit. Schweiz Rundsch Med Prax 1990;79:914–917

Luciani R, Carter D, Mannix L, et al. Prevention of migraine during prodrome with naratriptan. Cephalalgia Int J Headache 2000;20(2):122–126. doi:10.1046/j.1468-2982.2000.00030.x

doi: 10.1046/j.1468-2982.2000.00030.x

Maniyar FH, Sprenger T, Monteith T, Schankin C, Goadsby PJ. Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain 2014;137(1):232–241. doi:10.1093/brain/awt320

doi: 10.1093/brain/awt320

Karsan N, Bose RP, O’Daly O, Zelaya F, Goadsby PJ. Regional cerebral perfusion during the premonitory phase of triggered migraine: A double-blind randomized placebo-controlled functional imaging study using pseudo-continuous arterial spin labeling. Headache 2023;63(6):771–787. doi:10.1111/head.14538

doi: 10.1111/head.14538

Karsan N, Bose PR, O’Daly O, Zelaya FO, Goadsby PJ. Alterations in functional connectivity during different phases of the triggered migraine attack. Headache 2020;60(7):1244–1258. doi:10.1111/head.13865

doi: 10.1111/head.13865

Bartsch T, Goadsby PJ. Increased responses in trigeminocervical nociceptive neurons to cervical input after stimulation of the dura mater. Brain J Neurol 2003;126(Pt 8):1801–1813. doi:10.1093/brain/awg190

doi: 10.1093/brain/awg190

Schwedt TJ, Zuniga L, Chong CD. Low heat pain thresholds in migraineurs between attacks. Cephalalgia Int J Headache 2015;35(7):593–599. doi:10.1177/0333102414550417

doi: 10.1177/0333102414550417

Strupf M, Fraunberger B, Messlinger K, Namer B. Cyclic changes in sensations to painful stimuli in migraine patients. Cephalalgia 2019;39(5):585–596. doi:10.1177/0333102418793641

doi: 10.1177/0333102418793641

Uglem M, Omland PM, Nilsen KB, et al. Does pain sensitivity change by migraine phase? A blinded longitudinal study. Cephalalgia Int J Headache 2017;37(14):1337–1349. doi:10.1177/0333102416679955

doi: 10.1177/0333102416679955

Judit A, Sándor PS, Schoenen J. Habituation of visual and intensity dependence of auditory evoked cortical potentials tends to normalize just before and during the migraine attack. Cephalalgia Int J Headache 2000;20(8):714–719. doi:10.1111/j.1468-2982.2000.00122.x

doi: 10.1111/j.1468-2982.2000.00122.x

Martins IP, Westerfield M, Lopes M, Maruta C, Gil-da-Costa R. Brain state monitoring for the future prediction of migraine attacks. Cephalalgia Int J Headache 2020;40(3):255–265. doi:10.1177/0333102419877660

doi: 10.1177/0333102419877660

McKendrick AM, Chan YM, Vingrys AJ, Turpin A, Badcock DR. Daily vision testing can expose the prodromal phase of migraine. Cephalalgia Int J Headache 2018;38(9):1575–1584. doi:10.1177/0333102417741130

doi: 10.1177/0333102417741130

Casanova A, Vives-Mestres M, Donoghue S, Mian A, Martin PR. An observational study of self-reported migraine triggers and prospective evaluation of the relationships with occurrence of attacks enabled by a smartphone application (App). Headache 2022;62(10):1406–1415. doi:10.1111/head.14328

doi: 10.1111/head.14328

Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev 2017;97(2):553–622. doi:10.1152/physrev.00034.2015

doi: 10.1152/physrev.00034.2015

Schulte LH, Jürgens TP, May A. Photo-, osmo- and phonophobia in the premonitory phase of migraine: mistaking symptoms for triggers? J Headache Pain 2015;16:14. doi:10.1186/s10194-015-0495-7

doi: 10.1186/s10194-015-0495-7

Karsan N, Bose P, Newman J, Goadsby PJ. Are some patient-perceived migraine triggers simply early manifestations of the attack? J Neurol 2021;268(5):1885–1893. doi:10.1007/s00415-020-10344-1

doi: 10.1007/s00415-020-10344-1

Hansen JM, Lipton RB, Dodick DW, et al. Migraine headache is present in the aura phase: a prospective study. Neurology 2012;79(20):2044–2049. doi:10.1212/WNL.0b013e3182749eed

doi: 10.1212/WNL.0b013e3182749eed

Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995;1(7):658–660. doi:10.1038/nm0795-658

doi: 10.1038/nm0795-658

Denuelle M, Boulloche N, Payoux P, et al. A PET study of photophobia during spontaneous migraine attacks. Neurology 2011;76(3):213–218. doi:10.1212/WNL.0b013e3182074a57

doi: 10.1212/WNL.0b013e3182074a57

Maniyar FH, Sprenger T, Schankin C, Goadsby PJ. Photic hypersensitivity in the premonitory phase of migraine–a positron emission tomography study. Eur J Neurol 2014;21(9):1178–1183. doi:10.1111/ene.12451

doi: 10.1111/ene.12451

Denuelle M, Fabre N, Payoux P, Chollet F, Geraud G. Hypothalamic activation in spontaneous migraine attacks. Headache 2007;47(10):1418–1426. doi:10.1111/j.1526-4610.2007.00776.x

doi: 10.1111/j.1526-4610.2007.00776.x

May A, Kaube H, Büchel C, et al. Experimental cranial pain elicited by capsaicin: a PET study. Pain 1998;74(1):61–66. doi:10.1016/S0304-3959(97)00144-9

doi: 10.1016/S0304-3959(97)00144-9

Humphrey PPA, Feniuk W, Marriott AS, et al. Preclinical studies on the anti-migraine drug, sumatriptan. Eur Neurol 2008;31(5):282–290. doi:10.1159/000116755

doi: 10.1159/000116755

Johnson KW, Morin SM, Wroblewski VJ, Johnson MP. Peripheral and central nervous system distribution of the CGRP neutralizing antibody [125I] galcanezumab in male rats. Cephalalgia Int J Headache 2019;39(10):1241–1248. doi:10.1177/0333102419844711

doi: 10.1177/0333102419844711

Meylakh N, Marciszewski KK, Di Pietro F, et al. Brainstem functional oscillations across the migraine cycle: A longitudinal investigation. NeuroImage Clin 2021;30:102630. doi:10.1016/j.nicl.2021.102630

doi: 10.1016/j.nicl.2021.102630

Marciszewski KK, Meylakh N, Di Pietro F, et al. Changes in brainstem pain modulation circuitry function over the migraine cycle. J Neurosci Off J Soc Neurosci 2018;38(49):10479–10488. doi:10.1523/JNEUROSCI.1088-18.2018

doi: 10.1523/JNEUROSCI.1088-18.2018

Luedtke K, Schulte LH, May A. Visual processing in migraineurs depends on the migraine cycle. Ann Neurol 2019;85(2):280–283. doi:10.1002/ana.25398

doi: 10.1002/ana.25398

Goadsby PJ, Dodick DW, Almas M, et al. Treatment-emergent CNS symptoms following triptan therapy are part of the attack. Cephalalgia 2007;27:254–262. doi:10.1111/j.1468-2982.2007.01278

doi: 10.1111/j.1468-2982.2007.01278

Schulte LH, May A. The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks. Brain 2016;139:1987–1993. doi:10.1093/brain/aww097

doi: 10.1093/brain/aww097

Gil-Gouveia R, Martins IP. Clinical description of attack-related cognitive symptoms in migraine: A systematic review. Cephalalgia Int J Headache 2018;38(7):1335–1350. doi:10.1177/0333102417728250

doi: 10.1177/0333102417728250

Tso AR, Trujillo A, Guo CC, Goadsby PJ, Seeley WW. The anterior insula shows heightened interictal intrinsic connectivity in migraine without aura. Neurology 2015;84(10):1043–1050. doi:10.1212/WNL.0000000000001330

doi: 10.1212/WNL.0000000000001330

Hadjikhani N, Ward N, Boshyan J, et al. The missing link: enhanced functional connectivity between amygdala and visceroceptive cortex in migraine. Cephalalgia Int J Headache 2013;33(15):1264–1268. doi:10.1177/0333102413490344

doi: 10.1177/0333102413490344

Moulton EA, Becerra L, Johnson A, Burstein R, Borsook D. Altered hypothalamic functional connectivity with autonomic circuits and the locus coeruleus in migraine. PloS One 2014;9(4):e95508. doi:10.1371/journal.pone.0095508

doi: 10.1371/journal.pone.0095508

Moulton EA, Burstein R, Tully S, et al. Interictal dysfunction of a brainstem descending modulatory center in migraine patients. PloS One 2008;3(11):e3799. doi:10.1371/journal.pone.0003799

doi: 10.1371/journal.pone.0003799

Coppola G, Vandenheede M, Di Clemente L, et al. Somatosensory evoked high-frequency oscillations reflecting thalamo-cortical activity are decreased in migraine patients between attacks. Brain J Neurol 2005;128(Pt 1):98–103. doi:10.1093/brain/awh334

doi: 10.1093/brain/awh334

Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991;325(5):316–321. doi:10.1056/NEJM199108013250504

doi: 10.1056/NEJM199108013250504

Kuca B, Silberstein SD, Wietecha L, et al. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology 2018;91(24):e2222–e2232. doi:10.1212/WNL.0000000000006641

doi: 10.1212/WNL.0000000000006641

Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain J Neurol 2019;142(7):1894–1904. doi:10.1093/brain/awz134

doi: 10.1093/brain/awz134

Bouchelet I, Cohen Z, Case B, Séguéla P, Hamel E. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol Pharmacol 1996;50(2):219–223.

Bouchelet I, Case B, Olivier A, Hamel E. No contractile effect for 5-HT1D and 5-HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery. Br J Pharmacol 2000;129(3):501–508. doi:10.1038/sj.bjp.0703081

doi: 10.1038/sj.bjp.0703081

Barbanti P, Fofi L, Aurilia C, Egeo G. Dopaminergic symptoms in migraine. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 2013;34 Suppl 1:S67–70. doi:10.1007/s10072-013-1415-8

doi: 10.1007/s10072-013-1415-8

Barbanti P, Fabbrini G, Vanacore N, et al. Dopamine and migraine: does Parkinson’s disease modify migraine course? Cephalalgia Int J Headache 2000;20(8):720–723. doi:10.1111/j.1468-2982.2000.00123.x

doi: 10.1111/j.1468-2982.2000.00123.x

van Oosterhout WPJ, van Someren EJW, Louter MA, et al. Restless legs syndrome in migraine patients: prevalence and severity. Eur J Neurol 2016;23(6):1110–1116. doi:10.1111/ene.12993

doi: 10.1111/ene.12993

Charbit AR, Akerman S, Holland PR, Goadsby PJ. Neurons of the dopaminergic/calcitonin gene-related peptide A11 cell group modulate neuronal firing in the trigeminocervical complex: an electrophysiological and immunohistochemical study. J Neurosci Off J Soc Neurosci 2009;29(40):12532–12541. doi:10.1523/JNEUROSCI.2887-09.2009

doi: 10.1523/JNEUROSCI.2887-09.2009

Marmura MJ. Use of dopamine antagonists in treatment of migraine. Curr Treat Options Neurol 2012;14(1):27–35. doi:10.1007/s11940-011-0150-9

doi: 10.1007/s11940-011-0150-9

Sara SJ, Bouret S. Orienting and reorienting: the locus coeruleus mediates cognition through arousal. Neuron 2012;76(1):130–141. doi:10.1016/j.neuron.2012.09.011

doi: 10.1016/j.neuron.2012.09.011

Llorca-Torralba M, Borges G, Neto F, Mico JA, Berrocoso E. Noradrenergic locus coeruleus pathways in pain modulation. Neuroscience 2016;338:93–113. doi:10.1016/j.neuroscience.2016.05.057

doi: 10.1016/j.neuroscience.2016.05.057

Schwarz LA, Luo L. Organization of the locus coeruleus-norepinephrine system. Curr Biol CB 2015;25(21):R1051–R1056. doi:10.1016/j.cub.2015.09.039

doi: 10.1016/j.cub.2015.09.039

Vila-Pueyo M, Strother LC, Kefel M, Goadsby PJ, Holland PR. Divergent influences of the locus coeruleus on migraine pathophysiology. Pain 2019;160(2):385–394. doi:10.1097/j.pain.0000000000001421

doi: 10.1097/j.pain.0000000000001421

Wang F, Wang J, Cao Y, Xu Z. Serotonin-norepinephrine reuptake inhibitors for the prevention of migraine and vestibular migraine: a systematic review and meta-analysis. Reg Anesth Pain Med 2020;45(5):323–330. doi:10.1136/rapm-2019-101207

doi: 10.1136/rapm-2019-101207

Zagami AS, Goadsby PJ, Edvinsson L. Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides 1990;16(2):69–75. doi:10.1016/0143-4179(90)90114-e

doi: 10.1016/0143-4179(90)90114-e

Eftekhari S, Gaspar RC, Roberts R, et al. Localization of CGRP receptor components and receptor binding sites in rhesus monkey brainstem: A detailed study using in situ hybridization, immunofluorescence, and autoradiography. J Comp Neurol 2016;524(1):90–118. doi:10.1002/cne.23828

doi: 10.1002/cne.23828

Guo S, Vollesen ALH, Olesen J, Ashina M. Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migraine. Pain 2016;157(12):2773–2781. doi:10.1097/j.pain.0000000000000702

doi: 10.1097/j.pain.0000000000000702

Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia Int J Headache 2010;30(10):1179–1186. doi:10.1177/0333102410368444

doi: 10.1177/0333102410368444

Mason BN, Kaiser EA, Kuburas A, et al. Induction of migraine-like photophobic behavior in mice by both peripheral and central CGRP mechanisms. J Neurosci 2017;37(1):204–216. doi:10.1523/JNEUROSCI.2967-16.2016

doi: 10.1523/JNEUROSCI.2967-16.2016

Recober A, Kuburas A, Zhang Z, et al. Role of calcitonin gene-related peptide in light-aversive behavior: implications for migraine. J Neurosci 2009;29(27):8798–8804. doi:10.1523/JNEUROSCI.1727-09.2009

doi: 10.1523/JNEUROSCI.1727-09.2009

VanderPluym J, Dodick DW, Lipton RB, et al. Fremanezumab for preventive treatment of migraine: Functional status on headache-free days. Neurology 2018;91(12):e1152–e1165. doi:10.1212/01.wnl.0000544321.19316.40

doi: 10.1212/01.wnl.0000544321.19316.40

Riesco N, Cernuda-Morollón E, Martínez-Camblor P, et al. Relationship between serum levels of VIP, but not of CGRP, and cranial autonomic parasympathetic symptoms: A study in chronic migraine patients. Cephalalgia Int J Headache 2017;37(9):823–827. doi:10.1177/0333102416653232

doi: 10.1177/0333102416653232

Pellesi L, Al-Karagholi MAM, De Icco R, et al. Effect of vasoactive intestinal polypeptide on development of migraine headaches: a randomized clinical trial. JAMA Netw Open 2021;4(8):e2118543. doi:10.1001/jamanetworkopen.2021.18543

doi: 10.1001/jamanetworkopen.2021.18543

Schytz HW, Birk S, Wienecke T, et al. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain J Neurol 2009;132(Pt 1):16–25. doi:10.1093/brain/awn307

doi: 10.1093/brain/awn307

Zagami AS, Edvinsson L, Goadsby PJ. Pituitary adenylate cyclase activating polypeptide and migraine. Ann Clin Transl Neurol 2014;1(12):1036–1040. doi:10.1002/acn3.113

doi: 10.1002/acn3.113

Akerman S, Goadsby PJ. Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: relevance to migraine. Sci Transl Med 2015;7(308):308ra157. doi:10.1126/scitranslmed.aaa7557

doi: 10.1126/scitranslmed.aaa7557

Hoffmann J, Miller S, Martins-Oliveira M, et al. PAC1 receptor blockade reduces central nociceptive activity: new approach for primary headache? Pain 2020;161(7):1670–1681. doi:10.1097/j.pain.0000000000001858

doi: 10.1097/j.pain.0000000000001858

Lundbeck H. Lundbeck announces positive phase II Proof of Concept results with Lu AG09222 in migraine prevention. News Powered by Cision. Published April 19, 2023. Accessed October 3, 2023. news.cision.com/h--lundbeck-a-s/r/lundbeck-announces-positive-phase-ii-proof-of-concept-results-with-lu-ag09222-in-migraine-prevention,c3754245

Ghanizada H, Al-Karagholi MAM, Walker CS, et al. Amylin analog pramlintide induces migraine-like attacks in patients. Ann Neurol 2021;89(6):1157–1171. doi:10.1002/ana.26072

doi: 10.1002/ana.26072

Ghanizada H, Al-Karagholi MAM, Arngrim N, et al. Effect of adrenomedullin on migraine-like attacks in patients with migraine: a randomized crossover study. Neurology 2021;96(20):e2488–e2499. doi:10.1212/WNL.0000000000011930

doi: 10.1212/WNL.0000000000011930

Benbow T, Cairns BE. Dysregulation of the peripheral glutamatergic system: a key player in migraine pathogenesis? Cephalalgia Int J Headache 2021;41(11-12):1249–1261. doi:10.1177/03331024211017882

doi: 10.1177/03331024211017882

Storer RJ, Akerman S, Goadsby PJ. Characterization of opioid receptors that modulate nociceptive neurotransmission in the trigeminocervical complex. Br J Pharmacol 2003;138(2):317–324. doi:10.1038/sj.bjp.0705034

doi: 10.1038/sj.bjp.0705034

Akerman S, Holland PR, Lasalandra MP, Goadsby PJ. Endocannabinoids in the brainstem modulate dural trigeminovascular nociceptive traffic via CB1 and “triptan” receptors: implications in migraine. J Neurosci 2013;33(37):14869–14877. doi:10.1523/JNEUROSCI.0943-13.2013

doi: 10.1523/JNEUROSCI.0943-13.2013

Ashina M, Hansen JM, Á Dunga BO, Olesen J. Human models of migraine - short-term pain for long-term gain. Nat Rev Neurol 2017;13(12):713–724. doi:10.1038/nrneurol.2017.137

doi: 10.1038/nrneurol.2017.137

Karsan N, Bose PR, Thompson C, Newman J, Goadsby PJ. Headache and non-headache symptoms provoked by nitroglycerin in migraineurs: A human pharmacological triggering study. Cephalalgia 2020;40(8):828–841. doi:10.1177/0333102420910114

doi: 10.1177/0333102420910114

Høivik HO, Laurijssens BE, Harnisch LO, et al. Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache. Cephalalgia Int J Headache 2010;30(12):1458–1467. doi:10.1177/0333102410370875

doi: 10.1177/0333102410370875

Van der Schueren BJ, Lunnon MW, Laurijssens BE, et al. Does the unfavorable pharmacokinetic and pharmacodynamic profile of the iNOS inhibitor GW273629 lead to inefficacy in acute migraine? J Clin Pharmacol 2009;49(3):281–290. doi:10.1177/0091270008329548

doi: 10.1177/0091270008329548

Lassen LH, Ashina M, Christiansen I, Ulrich V, Olesen J. Nitric oxide synthase inhibition in migraine. Lancet Lond Engl 1997;349(9049):401–402. doi:10.1016/s0140-6736(97)80021-9

doi: 10.1016/s0140-6736(97)80021-9

Iversen H, Olesen J. Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs. Cephalalgia 1996;16(6):412–418. doi:10.1046/j.1468-2982.1996.1606412.x

doi: 10.1046/j.1468-2982.1996.1606412.x

Asghar M. Effects of glyceryl trinitrate and calcitonin gene-related peptide on BOLD signal and arterial diameter: Methodological studies by fMRI and MRA. Dan Med J 2012;59(7):B4489.

Wienholtz NKF, Christensen CE, Zhang DG, et al. Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised clinical trial. Cephalalgia Int J Headache 2021;41(6):731–748. doi:10.1177/0333102420975395

doi: 10.1177/0333102420975395

Falkenberg K, Dunga BÓ á, Guo S, Ashina M, Olesen J. Cilostazol induced migraine does not respond to sumatriptan in a double blind trial. J Headache Pain 2018;19(1):11. doi:10.1186/s10194-018-0841-7

doi: 10.1186/s10194-018-0841-7